<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03568890</url>
  </required_header>
  <id_info>
    <org_study_id>ANDES</org_study_id>
    <nct_id>NCT03568890</nct_id>
  </id_info>
  <brief_title>Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure</brief_title>
  <acronym>ANDES</acronym>
  <official_title>Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare short-term (8 weeks) anticoagulation therapy (DOAC)
      vs. antiplatelet therapy for the prevention of device thrombosis following transcatheter
      LAAC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transcatheter left atrial appendage closure (LAAC) has emerged as an alternative to
      anticoagulation for preventing thromboembolic events in patients with atrial fibrillation.
      Whereas most complications associated with LAAC have decreased over time, the occurrence of
      device thrombosis remains a concern, with an incidence of 1 to 17%. Antithrombotic therapy
      for preventing device thrombosis following LAAC has evolved empirically, with antiplatelet
      therapy being the most commonly prescribed treatment. However, the rates of device thrombosis
      post-LAAC remain relatively high and have not decreased over time despite of increasing
      operator/center experience and the arrival of newer generation devices. This is of particular
      concern if we consider that LAAC is a preventive treatment. Experimental and mechanistic
      studies have suggested enhanced thrombin generation (and not platelet activation) within the
      days-weeks following the procedure as the most important mechanism involved in device
      thrombosis and appropriate short-term anticoagulation therapy with DOAC should translate into
      a significant reduction in the rate of device thrombosis post-LAAC.

      Therefore, the objective of the study is to compare short-term (8 weeks) anticoagulation
      therapy (DOAC) vs. antiplatelet therapy for the prevention of device thrombosis following
      transcatheter LAAC.

      It is estimated tha 350 patients will take part in the study. Considering the lack of data on
      DOAC therapy post-LAAC, a blinded interim analysis will be performed after the inclusion of
      the first 150 patients. The final sample size will be adjusted following the results of the
      blinded interim analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device thrombosis</measure>
    <time_frame>2 months after LAAC</time_frame>
    <description>Evaluated by TEE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device thrombosis</measure>
    <time_frame>12 months after LAAC</time_frame>
    <description>Evaluated by TEE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic events</measure>
    <time_frame>2- and 12-month follow-up</time_frame>
    <description>Stroke, TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>2- and 12-month follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Left Atrial Appendage Closure</condition>
  <condition>Thrombosis</condition>
  <condition>Stroke</condition>
  <condition>TIA</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Anticoagulation therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Direct oral anticoagulants (rivaroxaban, dabigatran, apixaban, or edoxaban; with dosage according to guideline recommendations) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiplatelet therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dual antiplatelet therapy with clopidogrel -75 mg/day- and low dose aspirin -80 to 125 mg/day for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban, dabigatran, apixaban, or edoxaban</intervention_name>
    <description>Duration of treatment: 8 weeks</description>
    <arm_group_label>Anticoagulation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel -75 mg/day</intervention_name>
    <description>Duration of treatment: 8 weeks</description>
    <arm_group_label>Antiplatelet therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose aspirin -80 to 125 mg/day-</intervention_name>
    <description>Duration of treatment: 8 weeks</description>
    <arm_group_label>Antiplatelet therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successful transcatheter LAAC with any approved device

          -  Age≥18 years old

        Exclusion Criteria:

          -  Absolute contraindications for anticoagulation therapy

          -  Prior intracranial hemorrhage

          -  Contraindications for TEE

          -  Severe pericardial effusion within the first 24 hrs following LAAC

          -  Major/life-threatening bleeding within the first 24 hrs following LAAC

          -  Female subjects of childbearing potential without using highly effective methods of
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Josep Rodes-Cabau, MD</last_name>
    <phone>418-656-8711</phone>
    <email>josep.rodes@criucpq.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melanie Côté, MSc</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>2646</phone_ext>
    <email>melanie.cote@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Josep Rodes-Cabau</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Rodes-Cabau</last_name>
      <phone>4186568711</phone>
      <email>josep.rodes@criucpq.ulaval.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Asmarats L, Rodés-Cabau J. Percutaneous Left Atrial Appendage Closure: Current Devices and Clinical Outcomes. Circ Cardiovasc Interv. 2017 Nov;10(11). pii: e005359. doi: 10.1161/CIRCINTERVENTIONS.117.005359. Review.</citation>
    <PMID>29146668</PMID>
  </results_reference>
  <results_reference>
    <citation>Main ML, Fan D, Reddy VY, Holmes DR, Gordon NT, Coggins TR, House JA, Liao L, Rabineau D, Latus GG, Huber KC, Sievert H, Wright RF, Doshi SK, Douglas PS. Assessment of Device-Related Thrombus and Associated Clinical Outcomes With the WATCHMAN Left Atrial Appendage Closure Device for Embolic Protection in Patients With Atrial Fibrillation (from the PROTECT-AF Trial). Am J Cardiol. 2016 Apr 1;117(7):1127-34. doi: 10.1016/j.amjcard.2016.01.039. Epub 2016 Feb 1.</citation>
    <PMID>26993976</PMID>
  </results_reference>
  <results_reference>
    <citation>Saw J, Tzikas A, Shakir S, Gafoor S, Omran H, Nielsen-Kudsk JE, Kefer J, Aminian A, Berti S, Santoro G, Nietlispach F, Moschovitis A, Cruz-Gonzalez I, Stammen F, Tichelbäcker T, Freixa X, Ibrahim R, Schillinger W, Meier B, Sievert H, Gloekler S. Incidence and Clinical Impact of Device-Associated Thrombus and Peri-Device Leak Following Left Atrial Appendage Closure With the Amplatzer Cardiac Plug. JACC Cardiovasc Interv. 2017 Feb 27;10(4):391-399. doi: 10.1016/j.jcin.2016.11.029.</citation>
    <PMID>28231907</PMID>
  </results_reference>
  <results_reference>
    <citation>Tzikas A, Shakir S, Gafoor S, Omran H, Berti S, Santoro G, Kefer J, Landmesser U, Nielsen-Kudsk JE, Cruz-Gonzalez I, Sievert H, Tichelbäcker T, Kanagaratnam P, Nietlispach F, Aminian A, Kasch F, Freixa X, Danna P, Rezzaghi M, Vermeersch P, Stock F, Stolcova M, Costa M, Ibrahim R, Schillinger W, Meier B, Park JW. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2016 Feb;11(10):1170-9. doi: 10.4244/EIJY15M01_06.</citation>
    <PMID>25604089</PMID>
  </results_reference>
  <results_reference>
    <citation>Lempereur M, Aminian A, Freixa X, Gafoor S, Kefer J, Tzikas A, Legrand V, Saw J. Device-associated thrombus formation after left atrial appendage occlusion: A systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet. Catheter Cardiovasc Interv. 2017 Nov 1;90(5):E111-E121. doi: 10.1002/ccd.26903. Epub 2017 Feb 1. Review.</citation>
    <PMID>28145040</PMID>
  </results_reference>
  <results_reference>
    <citation>Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Pierre B, Abbey S, Fatemi M, Franceschi F, Guedeney P, Jacon P, Paziaud O, Venier S, Deharo JC, Gras D, Klug D, Mansourati J, Montalescot G, Piot O, Defaye P. Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation. J Am Coll Cardiol. 2018 Apr 10;71(14):1528-1536. doi: 10.1016/j.jacc.2018.01.076.</citation>
    <PMID>29622159</PMID>
  </results_reference>
  <results_reference>
    <citation>O'Hara C, O'Hara GE, Jacques F, Champagne J, Lemyre M, Charbonneau L, O'Connor K, Bernier M, Beaudoin J, Rodés-Cabau J, Paradis JM. Run With the Hare and Hunt With the Hounds: Watchman Device Surgical Resection in the Setting of Recurrent Device Related Thrombi in a Patient With Bleeding Diathesis. JACC Cardiovasc Interv. 2016 Dec 12;9(23):e223-e225. doi: 10.1016/j.jcin.2016.09.041.</citation>
    <PMID>27931603</PMID>
  </results_reference>
  <results_reference>
    <citation>Rodriguez-Gabella T, Nombela-Franco L, Regueiro A, Jiménez-Quevedo P, Champagne J, O'Hara G, Bernier M, Macaya C, Rodés-Cabau J. Single Antiplatelet Therapy Following Left Atrial Appendage Closure in Patients With Contraindication to Anticoagulation. J Am Coll Cardiol. 2016 Oct 25;68(17):1920-1921. doi: 10.1016/j.jacc.2016.08.016.</citation>
    <PMID>27765196</PMID>
  </results_reference>
  <results_reference>
    <citation>Jalal Z, Dinet ML, Combes N, Pillois X, Renou P, Sibon I, Iriart X, Thambo JB. Percutaneous left atrial appendage closure followed by single antiplatelet therapy: Short- and mid-term outcomes. Arch Cardiovasc Dis. 2017 Apr;110(4):242-249. doi: 10.1016/j.acvd.2016.09.006. Epub 2017 Jan 3.</citation>
    <PMID>28065447</PMID>
  </results_reference>
  <results_reference>
    <citation>Rodés-Cabau J, O'Hara G, Paradis JM, Bernier M, Rodriguez-Gabella T, Regueiro A, O'Connor K, Beaudoin J, Puri R, Côté M, Champagne J. Changes in Coagulation and Platelet Activation Markers Following Transcatheter Left Atrial Appendage Closure. Am J Cardiol. 2017 Jul 1;120(1):87-91. doi: 10.1016/j.amjcard.2017.03.253. Epub 2017 Apr 12.</citation>
    <PMID>28495432</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwartz RS, Holmes DR, Van Tassel RA, Hauser R, Henry TD, Mooney M, Matthews R, Doshi S, Jones RM, Virmani R. Left atrial appendage obliteration: mechanisms of healing and intracardiac integration. JACC Cardiovasc Interv. 2010 Aug;3(8):870-7. doi: 10.1016/j.jcin.2010.04.017.</citation>
    <PMID>20723861</PMID>
  </results_reference>
  <results_reference>
    <citation>Bass JL. Transcatheter occlusion of the left atrial appendage--experimental testing of a new Amplatzer device. Catheter Cardiovasc Interv. 2010 Aug 1;76(2):181-5. doi: 10.1002/ccd.22536.</citation>
    <PMID>20665856</PMID>
  </results_reference>
  <results_reference>
    <citation>Kar S, Hou D, Jones R, Werner D, Swanson L, Tischler B, Stein K, Huibregtse B, Ladich E, Kutys R, Virmani R. Impact of Watchman and Amplatzer devices on left atrial appendage adjacent structures and healing response in a canine model. JACC Cardiovasc Interv. 2014 Jul;7(7):801-9. doi: 10.1016/j.jcin.2014.03.003.</citation>
    <PMID>25060026</PMID>
  </results_reference>
  <results_reference>
    <citation>January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 Dec 2;130(23):2071-104. doi: 10.1161/CIR.0000000000000040. Epub 2014 Mar 28. Erratum in: Circulation. 2014 Dec 2;130(23):e270-1.</citation>
    <PMID>24682348</PMID>
  </results_reference>
  <results_reference>
    <citation>Verheugt FW, Granger CB. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet. 2015 Jul 18;386(9990):303-10. doi: 10.1016/S0140-6736(15)60245-8. Epub 2015 Mar 14. Review. Erratum in: Lancet. 2015 Jul 18;386(9990):248.</citation>
    <PMID>25777666</PMID>
  </results_reference>
  <results_reference>
    <citation>López-López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, Davies PA, Bodalia PN, Bryden PA, Welton NJ, Hollingworth W, Caldwell DM, Savović J, Dias S, Salisbury C, Eaton D, Stephens-Boal A, Sofat R. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017 Nov 28;359:j5058. doi: 10.1136/bmj.j5058. Review. Erratum in: BMJ. 2017 Dec 4;359:j5631. BMJ. 2018 May 23;361:k2295.</citation>
    <PMID>29183961</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</investigator_affiliation>
    <investigator_full_name>Josep Rodes-Cabau</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Left Atrial Appendage Closure</keyword>
  <keyword>Anticoagulation therapy</keyword>
  <keyword>Antiplatelet therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

